Kunz, P. L.;
de Bruin, M. A.;
Balise, R. R.;
Fisher, G. A.;
Ford, J. M.
Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Beteiligte:
Kunz, P. L.;
de Bruin, M. A.;
Balise, R. R.;
Fisher, G. A.;
Ford, J. M.
Erschienen:
American Society of Clinical Oncology (ASCO), 2009
Beschreibung:
<jats:p> e15686 </jats:p><jats:p> Background: There is no single standard chemotherapy regimen for the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. At Stanford Cancer Center (SCC) we regularly use a regimen of carboplatin and 5- fluorouracil (CF) or carboplatin and capecitabine (CX) for the treatment of these patients. Methods: A single institution retrospective review of patients with metastatic gastric and GEJ adenocarcinoma treated with CF or CX was conducted. Patients received carboplatin AUC 6 on day 1 and either 5-FU at 200 mg/m2/day (via continuous IV infusion) or capecitabine at 1,000 mg/m2 po BID for 14 days, repeated every 21 days. Only patients treated at SCC who received ≥ 2 cycles of chemotherapy were included. Results: Fourty-five patients were identified. The majority (62%) were male. Median age at diagnosis was 66 years. Twenty-nine (64%) had gastric and 16 (36%) had GEJ cancers. Thirty-six patients (80%) were chemotherapy-naïve. Twenty-nine (64%) had poorly differentiated and 10 (22%) had moderately differentiated adenocarcinomas; 13 (29%) had signet ring features. The average number of cycles administered was 5.4; one possible treatment-related death (2%) was identified. Median time to progression was 4.9 months and median overall survival was 7.3 months. Conclusions: CF and CX are well tolerated and yield acceptable outcomes in high-risk metastatic gastric and gastroesophageal junction cancers. The tolerability allows for the addition of novel targeted agents in future studies. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p>